Seagen, Inc. (SGEN)

166.80
NASDAQ
Prev Close 192.34
Day Low/High 164.63 / 180.00
52 Wk Low/High 90.57 / 213.94
Exchange NASDAQ
Shares Outstanding 174.00B
Market Cap 33.47B
P/E Ratio N/A
Div & Yield N.A. (N.A)
The Trader Daily

The Trader Daily

A HERO may still emerge.

The Lesson of Today's Session

The Lesson of Today's Session

Become more aggressive about the real valuations of companies.

The Trader Daily

The Trader Daily

The $193 level on the SPY will be key today.

The Trader Daily

The Trader Daily

Thursday's SPY trade plan will involve fading the edges,

What Makes a Bull Market?

What Makes a Bull Market?

You're looking at one.

Jim Cramer Says Keep an Eye on 'New Pharma' as an Investment Theme

Jim Cramer Says Keep an Eye on 'New Pharma' as an Investment Theme

TheStreet's Jim Cramer says newer pharmaceutical companies, like Celgene (CELG), Isis Pharmaceuticals (ISIS) and Seattle Genetics (SGEN), should be bought on any weakness because they have the potential to perform extremely well and may be better buys than Pfizer, Merck, Bristol-Myers and Eli Lilly.

Timing It Right in this Market (Part 2)

Timing It Right in this Market (Part 2)

For these kinds of growth stocks, you have no choice but to wait.

Timing It Right in this Market (Part 1)

Timing It Right in this Market (Part 1)

Here are some specific stocks working as parables right now.

Seductive Words of the Fisherman Skeptic

Seductive Words of the Fisherman Skeptic

It's sardonic, corroded commentary designed to keep your pole in the boat.

This Froth Has to Be Reined In

This Froth Has to Be Reined In

The public market is currently divorced from the dazzling IPOs -- and that's always a bad sign.

Earnings Roundup

Here is my compilation of last night's profit reports. 24 beats: W&T Offshore (WTI) Oasis Petroleum (OAS) Marathon Oil (MRO) Huntington Ingalls Industries (HII) Cognizant Technology Solutions (CTSH) Disney (DIS) Electronic Arts (EA) Regency Centers ...

Seattle Genetics downgraded at Needham

Seattle Genetics downgraded at Cantor

Seattle Genetics rated new Buy at Cantor

Seattle Genetics rated new Buy at Think

The Next Big Thing in Biotech: M&A

The Next Big Thing in Biotech: M&A

Senior columnist Adam Feuerstein says M&A is the next big thing in biotech.